A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | MicrobiomeTrials← Back to trialsNCT03417739
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
TERMINATEDPHASE2INTERVENTIONAL
Trial Details
Start: 2018-03-26Est. Completion: 2020-05-05
Enrollment target: 13 participants Locations- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Metastatic Uveal Melanoma
Because we suspect that the benefit of anti-PD-1 in metastatic UM patients could vary according to previous exposure to …
Paris, FranceCompleted Apr 28, 2025
Metastatic Uveal Melanoma
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to c…
Boston, United StatesEst. completion Oct 1, 2027